• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Semler Scientific Announces Appointment of Chief Financial Officer, Record Quarterly Revenues and Strategic Streamlining

    7/11/23 8:03:00 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $SMLR alert in real time by email

    SANTA CLARA, Calif., July 11, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced the appointment of a chief financial officer (CFO), record quarterly revenues expected for the second quarter of 2023 and a strategic streamlining.

    Semler Scientific, Inc. (PRNewsfoto/Semler Scientific, Inc.)

    "We are pleased to announce Ms. Renae Cormier will lead our accounting, finance, investor relations and business strategy efforts as chief financial officer," said Doug Murphy-Chutorian, Semler Scientific's interim chief executive officer. "In addition, we expect to report record high revenues for the quarter ending June 30, 2023. Furthermore, Semler Scientific will streamline its operations to provide enhanced efficiencies."

    Appointment of CFO

    Ms. Cormier has been named CFO effective July 10, 2023. She will play a pivotal role in shaping the company's financial strategy, seeking to improve operational efficiency, and supporting its continued growth and success.

    Ms. Cormier will continue as Semler Scientific's head of corporate communications and business strategy, a role she has held since May 2022. In this capacity, Ms. Cormier has led investor relations and has been instrumental in helping to shape corporate strategy. She has a strong background in finance and accounting, having worked as an investment analyst and auditor for several years before joining Semler Scientific.

    Second Quarter 2023 Revenues

    Semler Scientific expects its revenues for the second quarter ending June 30, 2023 will be the highest quarterly revenues in its history, driven by continued sales of QuantaFlo® to existing and new customers to test for peripheral arterial disease. More detailed financial information will be provided in the second quarter earnings release, expected on or around August 10, 2023.

    Strategic Corporate Streamlining

    Semler Scientific also announced a strategic plan to streamline operations and reduce employee headcount by approximately 30% by September 15, 2023. This plan is meant to be proactive and seeks to drive operational efficiency, while still providing high quality service to its customers.

    Semler Scientific currently estimates that it will incur severance costs in the range of $0.7 million to $0.9 million consisting of one-time termination benefits, which are expected to be paid by December 31, 2023. Semler Scientific anticipates this will result in a reduction in quarterly operating expenses of approximately $1.5 million to $2.0 million, which are expected to be realized during the fourth quarter ended December 31, 2023.

    About Semler Scientific, Inc.:

    Semler Scientific, Inc. develops, manufactures and markets innovative products and services that assist in evaluating and treating chronic diseases. Its flagship product, QuantaFlo®, which is patented and cleared by the U.S. Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo® test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD) and heart dysfunction (HD). QuantaFlo® is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). In addition, Semler Scientific has an agreement with Mellitus Health, Inc. (Mellitus) to exclusively market and distribute Insulin Insights™, an FDA cleared software product that recommends optimal insulin dosing for diabetic patients in the United States, including Puerto Rico. Semler Scientific has a minority investment in Mellitus, as well as Monarch Medical Technologies LLC, a privately held company whose product EndoTool® offers a technological solution for inpatient glycemic management. Additional information about Semler Scientific can be found at www.semlerscientific.com.

    Forward-Looking Statements

    This press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "believe," "goal," "may," "will," "intend," "expect," "anticipate," "estimate," "project," "would," "could," or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include express or implied statements regarding Semler Scientific's expected second quarter 2023 revenues; strategic streamlining efforts; and estimated severance costs and reduction in operating expenses, including timing thereof; among others. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific's actual results to differ materially from those discussed here; such as risks associated with quarterly closing adjustments, implementation of its strategic streamlining efforts along with those other risk factors detailed in Semler Scientific's filings with the Securities and Exchange Commission. These forward-looking statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.

    INVESTOR CONTACT:

    Susan A. Noonan

    S.A. Noonan Communications

    [email protected]

    917 513 5303

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/semler-scientific-announces-appointment-of-chief-financial-officer-record-quarterly-revenues-and-strategic-streamlining-301873841.html

    SOURCE Semler Scientific, Inc.

    Get the next $SMLR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SMLR

    DatePrice TargetRatingAnalyst
    11/2/2022$60.00 → $45.00Buy → Neutral
    B. Riley Securities
    3/7/2022$145.00 → $70.00Buy
    B. Riley Securities
    11/2/2021$175.00 → $145.00Buy
    B. Riley Securities
    10/26/2021$151.00 → $175.00Buy
    B. Riley Securities
    More analyst ratings

    $SMLR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Semler Scientific® Appoints Natalie Brunell to its Board of Directors

      CAMPBELL, Calif., May 19, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, announced the appointment of Natalie Brunell to its board of directors. This strategic addition reflects Semler Scientific's continued commitment to its Bitcoin treasury strategy and further strengthens its leadership within the Bitcoin community. "We are thrilled to welcome Natalie to our board of directors," said Eric Semler, chairman of Semler Sci

      5/19/25 8:00:00 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific® Reports First Quarter 2025 Financial Results, BTC Yield of 22.2% YTD; Now holds 3,808 BTC

      CAMPBELL, Calif., May 13, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its bitcoin holdings and other key performance indicators (KPIs). "We continue to accretively grow our bitcoin arsenal using operating cash flow and proceeds from debt and equity financings," said Eric Semler, chairman of Semler Scientific. "And we a

      5/13/25 4:01:00 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific® Announces Updated BTC & ATM Activity; Purchased Additional 165 BTC; Now Holds 3,467 BTC; YTD BTC Yield of 23.8%; Earnings Release Date and Conference Call for First Quarter 2025 Financial Results

      SANTA CLARA, Calif., April 30, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, its at-the-market equity offering (ATM) program and first quarter earnings release date and conference call. BTC Update Between April 25, 2025 and April 29, 2025, Semler Scientific acquired 165 bitcoins for $15.7 million with an average purchase price of $94,931 pe

      4/30/25 8:00:00 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SMLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

      SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

      12/12/24 4:16:00 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Semler Scientific Inc.

      SC 13G - Semler Scientific, Inc. (0001554859) (Subject)

      11/26/24 12:09:40 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

      SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

      11/12/24 4:15:46 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SMLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Semler Scientific downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Semler Scientific from Buy to Neutral and set a new price target of $45.00 from $60.00 previously

      11/2/22 6:23:13 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • B. Riley Securities reiterated coverage on Semler Scientific with a new price target

      B. Riley Securities reiterated coverage of Semler Scientific with a rating of Buy and set a new price target of $70.00 from $145.00 previously

      3/7/22 10:22:03 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • B. Riley Securities reiterated coverage on Semler Scientific with a new price target

      B. Riley Securities reiterated coverage of Semler Scientific with a rating of Buy and set a new price target of $145.00 from $175.00 previously

      11/2/21 10:00:22 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SMLR
    SEC Filings

    See more
    • Semler Scientific Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Semler Scientific, Inc. (0001554859) (Filer)

      6/4/25 5:00:25 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

      8-K - Semler Scientific, Inc. (0001554859) (Filer)

      6/4/25 8:00:10 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

      8-K - Semler Scientific, Inc. (0001554859) (Filer)

      5/23/25 8:00:12 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SMLR
    Financials

    Live finance-specific insights

    See more
    • Semler Scientific® Reports First Quarter 2025 Financial Results, BTC Yield of 22.2% YTD; Now holds 3,808 BTC

      CAMPBELL, Calif., May 13, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its bitcoin holdings and other key performance indicators (KPIs). "We continue to accretively grow our bitcoin arsenal using operating cash flow and proceeds from debt and equity financings," said Eric Semler, chairman of Semler Scientific. "And we a

      5/13/25 4:01:00 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific® Announces Updated BTC & ATM Activity; Purchased Additional 165 BTC; Now Holds 3,467 BTC; YTD BTC Yield of 23.8%; Earnings Release Date and Conference Call for First Quarter 2025 Financial Results

      SANTA CLARA, Calif., April 30, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, its at-the-market equity offering (ATM) program and first quarter earnings release date and conference call. BTC Update Between April 25, 2025 and April 29, 2025, Semler Scientific acquired 165 bitcoins for $15.7 million with an average purchase price of $94,931 pe

      4/30/25 8:00:00 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific® Announces Updated BTC & ATM Activity; Purchased Additional 111 BTC; Now Holds 3,303 BTC; YTD BTC Yield of 23.5%

      SANTA CLARA, Calif., April 25, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to assist its customers in evaluating and treating chronic diseases, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, as well as its at-the-market equity offering (ATM) programs. BTC Update Between February 14, 2025 and April 24, 2025, Semler Scientific acquired 111 bitcoins for $10.0 million with an average purchase price of $90,124 per bitcoin, inclusive of fees and expenses, using p

      4/25/25 8:00:00 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SMLR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Semler Eric was granted 1,318 shares and bought $1,896,500 worth of shares (50,000 units at $37.93), increasing direct ownership by 9% to 621,721 units (SEC Form 4)

      4 - Semler Scientific, Inc. (0001554859) (Issuer)

      11/12/24 6:05:40 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SMLR
    Leadership Updates

    Live Leadership Updates

    See more

    $SMLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Semler Scientific® Appoints Natalie Brunell to its Board of Directors

      CAMPBELL, Calif., May 19, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, announced the appointment of Natalie Brunell to its board of directors. This strategic addition reflects Semler Scientific's continued commitment to its Bitcoin treasury strategy and further strengthens its leadership within the Bitcoin community. "We are thrilled to welcome Natalie to our board of directors," said Eric Semler, chairman of Semler Sci

      5/19/25 8:00:00 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific Announces Appointment of Chief Financial Officer, Record Quarterly Revenues and Strategic Streamlining

      SANTA CLARA, Calif., July 11, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced the appointment of a chief financial officer (CFO), record quarterly revenues expected for the second quarter of 2023 and a strategic streamlining. "We are pleased to announce Ms. Renae Cormier will lead our accounting, finance, investor relations and business strategy efforts as chief financial officer," said Doug Murphy-Chuto

      7/11/23 8:03:00 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific Announces Appointment of Eric Semler and William Chang as Directors

      Eric Semler Appointed as Chairman SANTA CLARA, Calif., April 19, 2023 /PRNewswire/ -- - Semler Scientific, Inc. (NASDAQ:SMLR) today announced that Eric Semler and William H.C. Chang (together, the "Investors"), who collectively beneficially own more than 20% of Semler Scientific's outstanding shares, will immediately join Semler Scientific's board of directors as new independent directors. Mr. Semler will join the board as a Class II director standing for reelection at the 2023 annual meeting of stockholders and will be appointed as Chairman of the board, and Mr. Chang will join the board as a Class I director standing for reelection at the 2025 annual meeting of stockholders. The board will

      4/19/23 4:01:00 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Brunell Natalie

      4 - Semler Scientific, Inc. (0001554859) (Issuer)

      5/22/25 6:19:47 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Brunell Natalie

      3 - Semler Scientific, Inc. (0001554859) (Issuer)

      5/22/25 6:18:05 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Cormier Renae

      4 - Semler Scientific, Inc. (0001554859) (Issuer)

      5/5/25 9:12:05 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care